ACCC COVID-19 Resource Center & Listserv
for Insights on Providing Optimal Patient Care During the Pandemic.
Providing a VOICE for Texas' MULTIDISCIPLINARY CANCER CARE TEAMS and the PATIENTS THEY SERVE since 1988
Meetings & Education
Bolstering Patient Care with Decision Support Tools
Patient Advocacy Organizations
TxSCO Hurricane Harvey Recovery Resources
State & Federal Resources
Find A Clinical Trial
Off-Label Use Literature
National Professional Organizations
TxSCO Corporate Members
Become a Corporate Member
Industry News Archive
CMS Assigns New J-Codes for Rituxan and Rituxan Hycela
Effective January 1, 2019, the Centers for Medicare & Medicaid Services (CMS) has assigned new J-codes for Rituxan and Rituxan Hycela (Genentech, Inc.):
Injection, rituximab, 10 mg (replaces J-code J9310)
Injection, rituximab 10 mg and hyaluronidase
These codes are not all-inclusive; appropriate codes can vary by patient, setting of care and payer. Correct coding is the responsibility of the provider submitting the claim for the item or service. Please check with the payer to verify codes and special billing requirements.
Read more about the new J-codes for Rituxan and Rituxan Hycela here.
Tweets by OSSatACCC